Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Hallucinations (young adult, older person): look for an organic cause

Psychiatry and addiction medicine · Symptom or situation · updated 2026-11-08

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: Visual hallucinations in 15 to 60% of visually impaired people depending on the degree of visual loss (Charles Bonnet syndrome) and, over the course of the disease, in more than 80% of patients with Parkinson disease [1]

Young adult: first psychotic episode

Fasting sample.

Fasting laboratory tests

Urine tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Do not order

Older person: recent hallucinations

Laboratory tests (non-fasting)

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Atypical psychosis in an adolescent or young adult: treatable inherited metabolic diseases

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Sources (23)
  1. O'Brien J, Taylor JP, Ballard C, et al. Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. J Neurol Neurosurg Psychiatry. 2020;91(5):512-9.
  2. Krebs MO, Lejuste F. Psychoses débutantes : pour une prise en charge précoce et intégrée. Livret du Centre d'évaluation jeunes adultes-adolescents (C'JAAD), centre hospitalier Sainte-Anne, 2017 (synthèse des Australian Clinical Guidelines for Early Psychosis, 2e édition, 2016 ; édité avec le soutien d'un laboratoire pharmaceutique).
  3. Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry. 2016;50(5):410-472.
  4. Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). S3-Leitlinie Schizophrenie (living), Langfassung, AWMF-Registernummer 038-009, version MAGICapp du 17/10/2025 (fichier de décembre 2025).
  5. Dissaux N, Neyme P, Kim-Dufor DH, et al. Psychosis caused by a somatic condition: how to make the diagnosis? A systematic literature review. Children (Basel). 2023;10(9):1439.
  6. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178, février 2014, dernière mise à jour le 4 septembre 2026.
  7. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : chapitre 14 (médicaments, toxiques), actes 1659 et 0659.
  8. American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition. Washington, DC : APA, 2020 (tableau 2, repris dans le diaporama de formation officiel de l'APA).
  9. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-22.
  10. Scottish Intercollegiate Guidelines Network. SIGN 157: Risk reduction and management of delirium. Mars 2019.
  11. Haute Autorité de santé. Confusion aiguë chez la personne âgée : prise en charge initiale de l'agitation. Recommandations de bonne pratique, mai 2009.
  12. Veauthier B, Hornecker JR, Thrasher T. Recent-Onset Altered Mental Status: Evaluation and Management. Am Fam Physician. 2021;104(5):461-470.
  13. Badcock JC, Larøi F, Kamp K, et al. Hallucinations in older adults: a practical review. Schizophr Bull. 2020;46(6):1382-95.
  14. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. Clinical guideline CG103, 28 juillet 2010, dernière mise à jour le 18 janvier 2023.
  15. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline NG97, 20 juin 2018.
  16. Centre de référence de la maladie de Wilson et autres maladies rares liées au cuivre. Protocole national de diagnostic et de soins (PNDS) : maladie de Wilson, 8 novembre 2021, et synthèse à destination du médecin traitant (Haute Autorité de santé, novembre 2021).
  17. Demily C, Sedel F. Psychiatric manifestations of treatable hereditary metabolic disorders in adults. Ann Gen Psychiatry 2014;13:27.
  18. Bonnot O, Klünemann HH, Sedel F, Tordjman S, Cohen D, Walterfang M. Diagnostic and treatment implications of psychosis secondary to treatable metabolic disorders in adults: a systematic review. Orphanet J Rare Dis 2014;9:65.
  19. Morris AA, Kožich V, Santra S, Andria G, Ben-Omran TI, Chakrapani AB, et al. Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency. J Inherit Metab Dis 2017;40(1):49-74.
  20. Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review. Gastroenterology 2023;164(3):484-491.
  21. Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis 2012;7:32.
  22. Geberhiwot T, Moro A, Dardis A, Ramaswami U, Sirrs S, Marfa MP, et al. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis 2018;13(1):50.
  23. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0547 (cuprémie), 1809 (céruloplasmine), 2008 (cuivre urinaire), 0637-0638 (porphyrines urinaires).